Edwards Lifesciences (NYSE:EW) VP Sells $974,446.20 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $85.93, for a total value of $974,446.20. Following the transaction, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,827,387.38. This trade represents a 34.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Edwards Lifesciences Price Performance

NYSE EW traded up $0.80 during trading hours on Monday, reaching $87.27. The company’s stock had a trading volume of 3,749,377 shares, compared to its average volume of 4,519,282. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The company’s 50-day moving average is $82.74 and its two-hundred day moving average is $81.27. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The stock has a market cap of $50.69 billion, a PE ratio of 47.69, a PEG ratio of 2.26 and a beta of 0.94.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same period last year, the company earned $0.59 EPS. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on EW shares. Canaccord Genuity Group set a $87.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, December 17th. Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $90.00 to $100.00 in a research note on Thursday, December 18th. Citigroup reissued a “buy” rating and issued a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Finally, TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Edwards Lifesciences by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after purchasing an additional 365,581 shares in the last quarter. State Street Corp increased its holdings in shares of Edwards Lifesciences by 1.5% in the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock valued at $2,215,777,000 after purchasing an additional 371,892 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Edwards Lifesciences by 4.8% during the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after purchasing an additional 989,533 shares during the period. Bank of New York Mellon Corp increased its stake in Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares during the period. Finally, Jennison Associates LLC grew its holdings in shares of Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after acquiring an additional 2,287,783 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.